The Current Ratio as of November 2024 (TTM) for Viridian Therapeutics, Inc. (VRDN) is 18.55

According to Viridian Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 18.55. This represents a change of -3.16% compared to the average of 19.16 of the last 4 quarters.

Viridian Therapeutics, Inc. (VRDN) Historical Current Ratio (quarterly & annually)

How has VRDN Current Ratio performed in the past?

The mean historical Current Ratio of Viridian Therapeutics, Inc. over the last ten years is 9.29. The current 18.55 Current Ratio has changed 19.88% with respect to the historical average. Over the past ten years (40 quarters), VRDN's Current Ratio was at its highest in in the March 2024 quarter at 23.99. The Current Ratio was at its lowest in in the December 2016 quarter at 0.93.

Viridian Therapeutics, Inc. (VRDN) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Viridian Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Viridian Therapeutics, Inc. (VRDN) Average Current Ratio

How has VRDN Current Ratio performed in the past?

The current Current Ratio of Viridian Therapeutics, Inc. (VRDN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Viridian Therapeutics, Inc. (VRDN) Current Ratio vs. Peers

How is VRDN’s Current Ratio compared to its peers?

Viridian Therapeutics, Inc.’s Current Ratio is less than Nuvalent, Inc. (23.07), less than DICE Therapeutics, Inc. (38.14), greater than Arcellx, Inc. (4.29), greater than Vaxcyte, Inc. (17.88), greater than Crinetics Pharmaceuticals, Inc. (16.38), greater than Cytokinetics, Incorporated (9.28), less than Structure Therapeutics Inc. (27.63), greater than Icosavax, Inc. (18.06), greater than Pliant Therapeutics, Inc. (10.26), greater than Syndax Pharmaceuticals, Inc. (6.99), greater than Revolution Medicines, Inc. (14.24), greater than Inozyme Pharma, Inc. (7.68), less than Terns Pharmaceuticals, Inc. (32.99), greater than Blueprint Medicines Corporation (3.32), greater than 89bio, Inc. (11.66), greater than Kura Oncology, Inc. (11.47), greater than Protagonist Therapeutics, Inc. (10.70), greater than Merus N.V. (8.32), greater than Replimune Group, Inc. (10.11), greater than Cerevel Therapeutics Holdings, Inc. (10.22),

Build a custom stock screener for Viridian Therapeutics, Inc. (VRDN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Viridian Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Viridian Therapeutics, Inc. (VRDN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Viridian Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.